Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera Post author:Sam Post published:January 25, 2018 Post category:BioPharma The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy. Source: BioSpace You Might Also Like This Bay Area Biotech Snags $293 Million Pain Drug Pact With Novartis AG May 7, 2017 Pfizer to Hire Up to 400 in Michigan for 2018 November 12, 2017 Booming Lakepharma to Create 100 New Jobs in Massachusetts Expansion February 12, 2018
